

# MALE CANCERS AND SPECIFIC REQUESTS FOR SEXUAL CARE

## LESSONS FOR DAILY PRACTICE BASED ON 3 PROSPECTIVE SURVEYS IN AN OUTPATIENT UROLOGY CLINIC IN PUBLIC HOSPITAL

Pierre BONDIL\*, Daniel HABOLD\*\*, Tony DAMIANO\*\*\*

Department of Urology-andrology General Hospital, Chambéry 73011 FRANCE

\* urologist-oncologist-sexologist \*\* oncosexologist, \*\*\* ROSA pierre.bondil@ch-chambery.fr



ROSA

**Abstract:** In order to better specify our needs in oncosexology, prospective investigations were made among successive cancer male outpatient populations (n = 983), first all cancers (AC) then prostate cancer (PC) consulting in urology whatever the stage, treatment or follow-up. **Material and method:** All cancer: investigation of exclusive patient requests followed by a specific treatment for sexual problems among 615 successive male outpatients with cancer. Five analyzed parameters: age, sexual problems, cancers and concerned treatments, effected sexual treatments, referral physician. **PC :** proactive analysis of: a) erectile capacity (Hardness Erectile Score: HES), b) eventual demand for treatment, c) survey well-founded in successive 246 all ages patients (mean age: 70.6) then only in 122 ageing (> 74 years) ones. **Results :** All cancer: sexual troubles treatment: only for 126 patients (20.5%) i.e. 114 erectile dysfunction (ED), 5 lowering of desire and 7 miscellaneous; concerned cancers: only 8% non urological; specific treatment: mainly pharmacological using oral PDE5 inhibitors (PDE5i) (n=50), PGE1 intracavernous injections (ICI) (n=48) or associations (n=10); referral physicians: only 10% patients specifically sent by other physicians. **PC:** a) all age: 18% no ED (mean HES 3.7) vs. 82% ED (HES score < 3); treatment demand = 48% (43 PDE5i, 42 ICI, 12 other); survey approval = 95%; b) ageing: 7% no ED vs. 93% ED; treatment demand (9%) or already treated (19%); survey approval (99%). In our 368 unselected PC outpatients, 20% have no ED problem, 40% ask for or are treated. If 40% are not interested in a treatment, 95% agree to be questioned and informed about the potential impact of PC treatments on sexual health and intimacy. **Conclusion:** In spite of several limitations, these observational investigations show 5 facts: 1) a minority (20.5%) of our all cancers patients benefits from specific care concerning mainly ED (90%), PC (79%) and pharmacological treatments (89%), 2) the low number of non urological cancers (8%) reflects an inequality of access to oncosexological care, 3) 82% of our all ages PC patients have ED but only half is treated, 4) when proactively asked, 95% wanted specific information or treatment even the older ones proving a contrast between both "sexual" interest and survey approval and ED treatment demand, d) a paradoxical situation in CP group: overestimation of ED negative impact in youngest population vs. underestimation of sexual interest in oldest one.

### CONTEXT


• To cure the cancer without sequels in order to preserve the quality of life = a real challenge.

• Sexual and intimacy difficulties induced by cancer or its treatment usually impair both quality of life and well-being of patients and couples.

• On 2008, according to our hospital plan, 2 specific oncosexological consultations were set up in 2 different sites :

➢ urology (Dr P Bondil MD)

➢ supportive care centre (Dr D Habold MD)



### OBJECTIVE

• In order to better evaluate our needs in oncosexology, several surveys were made among successive cancer male outpatient population consulting in urology whatever the stage, treatment or follow-up : 1) all cancers (AC), 2) exclusive prostate cancers (PC) with 2 aims:

➢ quantitative : to better evaluate the potential number of patients.

➢ qualitative : to better identify their different requests, treatments, needs.

### MATERIAL AND METHODS

• 615 consecutive consultants with cancer (41%) whatever the stage / treatment / follow-up of cancer

▪ Analysis of exclusive patient requests for sexual problems followed by a specific treatment (i.e. only reactive action)

▪ 5 analyzed parameters

1. age
2. sexual problems involved
3. cancers and treatments involved
4. effected treatments
5. referral physician.

1st group (NSC) non selected cancer patients

2nd group (CP) exclusive cancer prostate patients

	all ages	> 74 year
number	246	122
mean age	70.6	79.8

• 3 prospective surveys among 2 successive populations (all cancers then only prostate cancer)

• Choice of sample = arbitrary for practical reasons

• only male cancer outpatients +++

• consulting in the urology site ++

• concerning a single physician (P Bondil)

• Surveys = observational in selected male outpatient samples (n = 983)



• Two different exclusive prostate cancer (PC) populations

- 1st = successive all age outpatients

- 2nd = successive ageing (> 74 years old) outpatients

• Both samples = whatever the PC treatment, stage, follow-up

• Proactive +++ analysis of 6 parameters in 368 consecutive patients

1. age

2. PC treatment

3. erectile capacity\* (ED if EHS < 3)

4. specific erectile dysfunction (ED) treatment

5. eventual interest for ED treatment or not

6. survey well-founded

\* erectile capacity quoted from 1 to 4 according to HES erection hardness score J Sex Med 2007.

2nd group (PC) exclusive prostate cancer patients

3 successive surveys

1st survey

2nd survey


3rd survey

March 2008 to September 2008

July 2009 to November 2009

October 2010 to May 2011

Evaluation of erectile capacity by using the visual EHS questionnaire



Severe ED = 1  
Moderate ED = 2  
Mild ED = 3  
No ED = 4

ED if EHS < 3

